{
  "abstract": "Introduction The Pipeline Vantage Flow Diverter was developed with a novel design aimed at improved delivery, wall apposition, and reduced thrombogenicity. Data on mid-term outcomes remain limited and scrutiny regarding the device has heightend following a U.S. Food and Drug Administration (FDA) recall of the PVED 0.027’ version due to reports of incomplete wall apposition and braid deformation (‘fish-mouthing’).Aim of study In this report we describe mid-term outcomes of a single centre study evaluating the safety and efficacy of the Pipeline Vantage Flow Diverter, expanding on initial findings from earlier short-term series.Method We retrospectively collected data across a single centre on consecutive patients with intracranial aneurysms treated with the Pipeline Vantage Flow Diverter. Key endpoints included procedure-related technical success, complications, and mid-term radiological occlusion rates.Results A total of 58 patients underwent 58 treatments for 78 aneurysms with the Pipeline Vantage Flow Diverter. Imaging follow-up at a median of 19 (IQR 6; Range: 1–42) months revealed RROC1 (83.1%) followed by RROC2 (8.5%), RROC3a (5.1%), and RROC3b (3.4%). Favourable occlusion occurred in 54 (91.5%). None required retreatment. Procedure related mortality was 0%. There were five (8.2%) ischaemic events and one (1.6%) intracranial haemorrhage, causing persisting neurological deficit in three (4.9%) and transient deficit in three (4.9%). Subset analysis showed no difference in imaging outcomes or adverse events in those treated with the 0.021’ versus 0.027’ system.Conclusion In this mid-term evaluation, the Pipeline Vantage Flow Diverter demonstrated high rates of aneurysm occlusion with an acceptable safety profile.Conflict of Interest No",
  "authors": [
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Sahan Guruge"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Matthew Benger"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Gian Marco Frigerio"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Sara Sciacca"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Naga Kandasamy"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Thomas Booth"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Parthiban Balasundaram"
    },
    {
      "affiliations": [
        "King’s College Hospital, London, UK"
      ],
      "name": "Jeremy Lynch"
    }
  ],
  "title": "A166 Mid term outcomes of the pipeline vantage flow diverter",
  "uid": "56380bd3-23b3-5bd6-bff4-1a0e20da91a4"
}